Accéder au contenu
Merck

The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia.

AJNR. American journal of neuroradiology (2009-02-28)
A S Vagal, J L Leach, M Fernandez-Ulloa, M Zuccarello
RÉSUMÉ

The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation is compromised. Identification of the presence and degree of autoregulatory vasodilation (reflecting the cerebrovascular reserve) is a significant prognostic factor in patients with chronic cerebrovascular disease. The pharmacologic challenge of a vasodilatory stimulus such as ACZ can also be used to optimize the treatment strategies for these patients. The pathophysiology, methods, and clinical applications of the ACZ challenge test are discussed in this article.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acetazolamide, ≥99%, powder
USP
Acetazolamide, United States Pharmacopeia (USP) Reference Standard
Acetazolamide, European Pharmacopoeia (EP) Reference Standard
Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard